Press Releases

Olivier Marcq Joins Tubulis as Vice President CMC

We are excited to welcome a new colleague to the Tubulis Team. Olivier Marcq joins us as Vice President CMC. He is an expert in bioconjugation therapeutics with more than 15 years of leadership expertise in the pharmaceutical industry, including big pharma companies, such as Pfizer and Astellas Pharma, as well as biotech start-ups. His profound experience encompasses CMC operation and strategy and GMP manufacturing as well as R&D and early phase development of biologics, particularly ADCs and conjugate vaccines. Olivier will use his long-standing know-how to advance and accelerate the development of our uniquely matched, next-generation ADC candidates towards clinical evaluation.


For Tubulis
Dominik Schumacher,
CEO & Co-Founder
Phone: +49 175 800 5594

Media Requests for Tubulis
Trophic Communications
Stephanie May or Marie Weickert
Phone: + 49 171 185 5682

Share Article

More Press Releases

Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024